SLC5A2 and diabetes mellitus: Next, a small RCT trial, the Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-diabetic Patients With Chronic Kidney Disease (DIAMOND trial), on non-diabetes patients with proteinuric kidney disease found no significant benefits [25].